MA52618A - Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses - Google Patents

Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses

Info

Publication number
MA52618A
MA52618A MA052618A MA52618A MA52618A MA 52618 A MA52618 A MA 52618A MA 052618 A MA052618 A MA 052618A MA 52618 A MA52618 A MA 52618A MA 52618 A MA52618 A MA 52618A
Authority
MA
Morocco
Prior art keywords
yle
thiazol
treatment
diseases associated
fiber sensitization
Prior art date
Application number
MA052618A
Other languages
English (en)
Inventor
Damian Brockschnieder
Oliver Martin Fischer
Christian Friedrich
Isabella Gashaw
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA52618A publication Critical patent/MA52618A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA052618A 2018-05-15 2019-05-14 Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses MA52618A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18172409 2018-05-15

Publications (1)

Publication Number Publication Date
MA52618A true MA52618A (fr) 2021-04-21

Family

ID=62186254

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052618A MA52618A (fr) 2018-05-15 2019-05-14 Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses

Country Status (16)

Country Link
US (1) US20210220358A1 (fr)
EP (1) EP3793554A1 (fr)
JP (1) JP2021523919A (fr)
KR (1) KR20210009341A (fr)
CN (1) CN112334132A (fr)
AU (1) AU2019269049A1 (fr)
BR (1) BR112020022553A2 (fr)
CA (1) CA3100099A1 (fr)
CL (1) CL2020002939A1 (fr)
EA (1) EA202092678A1 (fr)
JO (1) JOP20200286A1 (fr)
MA (1) MA52618A (fr)
MX (1) MX2020012202A (fr)
SG (1) SG11202011010YA (fr)
TW (1) TWI780329B (fr)
WO (1) WO2019219674A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6544665B2 (ja) 2014-12-09 2019-07-17 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
PL3862000T3 (pl) 2018-10-05 2024-03-18 Shionogi & Co., Ltd Lek na przewlekły kaszel
GB201908219D0 (en) 2019-06-10 2019-07-24 Axalbion Sa Therapeutic use of a compound
EP3757103A1 (fr) * 2019-06-27 2020-12-30 Bayer AG Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
WO2021238834A1 (fr) * 2020-05-25 2021-12-02 中国医药研究开发中心有限公司 Composé arylformamide et son procédé de préparation et son utilisation médicale
WO2022068930A1 (fr) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 Composé benzamide et son utilisation
WO2022253943A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes cristallines de 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}-benzamide
WO2022253945A1 (fr) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Formes posologiques pharmaceutiques comprenant du 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}-benzamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CN101981003B (zh) * 2008-02-29 2014-07-02 伊沃泰克股份公司 酰胺化合物、组合物及其应用
CR20160093A (es) 2013-08-23 2016-08-26 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
JP6544665B2 (ja) * 2014-12-09 2019-07-17 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
PT3355889T (pt) * 2015-09-29 2023-04-26 Afferent Pharmaceuticals Inc Moduladores de recetores de diaminopirimidina p2x3 e p2x2/3 para utilização no tratamento da tosse
JP2021523201A (ja) * 2018-05-15 2021-09-02 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド

Also Published As

Publication number Publication date
EA202092678A1 (ru) 2021-04-12
SG11202011010YA (en) 2020-12-30
MX2020012202A (es) 2021-01-29
TWI780329B (zh) 2022-10-11
BR112020022553A2 (pt) 2021-02-02
CA3100099A1 (fr) 2019-11-21
CL2020002939A1 (es) 2021-03-05
JOP20200286A1 (ar) 2020-11-09
EP3793554A1 (fr) 2021-03-24
TW201946924A (zh) 2019-12-16
AU2019269049A1 (en) 2020-11-26
WO2019219674A1 (fr) 2019-11-21
JP2021523919A (ja) 2021-09-09
KR20210009341A (ko) 2021-01-26
CN112334132A (zh) 2021-02-05
US20210220358A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
MA52616A (fr) Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
IL282624A (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
MA41841A (fr) Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
EP3463315A4 (fr) Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MA51524A (fr) Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
MA52415A (fr) Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
EP4045036A4 (fr) Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1
MA52778A (fr) Méthodes de traitement de troubles associés au récepteur s1p1
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3773491A4 (fr) Méthodes de traitement de troubles associés à l'apoe4/4
EP3504204A4 (fr) Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
EP3621434A4 (fr) Méthodes de traitement de troubles neuropsychiatriques
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP3873496A4 (fr) Traitement de l'hypoxie cérébrale comprenant l'accident vasculaire cérébral, l'encéphalopathie traumatique chronique et la lésion cérébrale traumatique
EP4021432A4 (fr) Eskétamine pour le traitement de patients présentant un trouble dépressif majeur, notamment la suicidalité
EP3709982A4 (fr) Composés, compositions et méthodes pour le traitement de troubles oculaires et de maladies cutanées